Group 1 - Yunzhi Voice Technology Co., Ltd. listed on the Hong Kong Stock Exchange on June 30, becoming the "first AGI stock" in Hong Kong [1] - Yunzhi was founded in 2012 and has developed AI solutions based on deep learning models, including its core algorithm model UniCore [1] - The company has received investments from notable institutions such as Sequoia Capital, JD.com, and Qualcomm, with a significant investment from Sichuan Innovation and Entrepreneurship Equity Investment Fund in 2017 [1] Group 2 - Moore Threads submitted its prospectus for listing on the Sci-Tech Innovation Board, focusing on full-function GPU chip development [2] - The company supports various workloads including AI computing acceleration and 3D graphics rendering [2] - Chengdu Ciyuan Guoyi Electronic Information Equity Investment Fund invested in Moore Threads in 2023 [2] Group 3 - Wuhan Heyuan Biotechnology Co., Ltd. is preparing for an IPO on the Sci-Tech Innovation Board, with its core product HY1001 nearing market approval [2] - HY1001 is a new drug that has completed Phase III clinical trials and is under priority review by the National Medical Products Administration [2] Group 4 - Yaoke Ankang Technology Co., Ltd. successfully listed on the Hong Kong Stock Exchange on June 23, with significant investment from the National Investment (Guangdong) Technology Achievement Transformation Venture Capital Fund [5] - The company focuses on innovative drug development for cancer, inflammation, and cardiovascular diseases, with multiple candidates in clinical stages [5] Group 5 - Sichuan Southwest Jiaotong Railway Development Co., Ltd. listed on the Beijing Stock Exchange on June 10, specializing in rail transportation infrastructure safety [6] - The company is recognized as a national-level "little giant" enterprise and is the first IPO project of the Sichuan Science and Technology Investment's Academician Fund [6] - Multiple local funds, including Chengdu Lixin Jingrong Fund, participated in the investment of Jiaotong Railway Development [6]

Core Viewpoint - Chengdu Xian Dao Pharmaceutical Development Co., Ltd. has terminated its acquisition of Nanjing Haina Pharmaceutical Technology Co., Ltd. due to failure to reach consensus on key transaction terms, but it does not expect any adverse impact on its business operations or financial status [1][3]. Company Overview - Chengdu Xian Dao is a rapidly developing biotechnology company focused on new drug research and development, listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board since April 2020 [7]. - The company has experienced revenue fluctuations post-IPO, but has shown stable growth in recent years, with projected revenues of 4.27 billion yuan for 2024, reflecting a year-on-year growth of 14.99% [7]. Financial Performance - Chengdu Xian Dao's revenue from 2020 to 2024 is reported as follows: 2.44 billion yuan, 3.11 billion yuan, 3.30 billion yuan, 3.71 billion yuan, and 4.27 billion yuan, with year-on-year changes of -7.8%, 27.69%, 5.98%, 12.64%, and 14.99% respectively [7]. - The net profit attributable to shareholders for the same period is 640.2 million yuan, 633.8 million yuan, 252.7 million yuan, 407.2 million yuan, and 513.6 million yuan, with year-on-year changes of -46.77%, -1.00%, -60.14%, 61.16%, and 26.13% respectively [7]. Shareholder Activity - Since 2024, Chengdu Xian Dao has faced frequent shareholder reductions, with a total cash-out of 294 million yuan [8]. - Specific instances of share reductions include a 1.20% stake sold for 78.98 million yuan and a 0.50% stake sold for 31.75 million yuan [9]. Nanjing Haina Pharmaceutical Overview - Nanjing Haina is focused on improved innovative drugs and high-end generic drugs, operating under a "CXO + MAH" business model [3]. - The company submitted an IPO application in June 2023, aiming to raise 850 million yuan, but its application was terminated in June 2024 due to the withdrawal of its sponsor [3][4]. Financial Performance of Nanjing Haina - Nanjing Haina's revenue from 2020 to 2023 is reported as follows: 56.82 million yuan, 168 million yuan, 271 million yuan, and 226 million yuan, with a compound annual growth rate of 118.37% from 2020 to 2022 [4]. - The net profit attributable to shareholders for the same period is -28.71 million yuan, 11.57 million yuan, 68.02 million yuan, and 73.18 million yuan [4]. - As of June 30, 2023, Nanjing Haina's undistributed profits stood at -142 million yuan [4]. Sales and Accounts Receivable - Nanjing Haina's sales expenses have increased significantly, with figures of 3.94 million yuan, 14.46 million yuan, 21.88 million yuan, and 15.41 million yuan over the same period, resulting in a sales expense ratio that is nearly double the industry average [5]. - Accounts receivable have also risen sharply, with balances of 3.01 million yuan, 20.33 million yuan, 41.85 million yuan, and 83.49 million yuan, reflecting a compound growth rate of 269.1% from 2020 to 2022 [5].

Group 1 - The core viewpoint of the article is the issuance of measures by the National Healthcare Security Administration and the National Health Commission to support the high-quality development of innovative drugs, particularly encouraging commercial health insurance to expand investment in innovative drugs [1] Group 2 - The measures encourage commercial health insurance companies to provide stable and long-term investment for innovative drug research and development through various means, such as innovative drug investment funds [1] - The initiative aims to cultivate patient capital that supports innovative drugs [1]

格蓝若机器人团队正在进行机器人研发攻关。 长江日报记者徐丹 摄 【开栏的话】 今天，我们迎来中国共产党成立104周年。本报今起推出"英雄城市·先锋有我"专栏，深 入挖掘一批基层党组织和党员立足岗位、干事创业的生动实践和典型事迹，展示全市广大党 员提能力、转作风、拼业绩、比贡献的新气象，为支点建设、转型发展凝聚先锋力量。 □ 长江日报记者徐丹 通讯员顾澳丽 6月30日，武汉格蓝若智能机器人有限公司（以下简称"格蓝若"）实验室内，工程师们 正紧张测试"大壮""小壮"和机器狗。随着项目管理主管陈燕一声令下，机器人稳健迈步，数 据曲线完美吻合，现场响起热烈掌声。 科技创新发展需要党建工作的有力引领。格蓝若党支部秉持"先锋领航"实践和拼搏精 神，短短7个月，让人形机器人实现从0到1的突破，生动践行了科技自立自强的使命担当。 ■ 突击队立下军令状 身高1.8米、体重95公斤，采用自主研发的运动控制算法，可负重40～60公斤并实现直 膝行走……这是格蓝若常务副总经理熊少华带领的格蓝若"党员先锋队"与华中科技大学陈学 东院士团队联合研发的"劳动者"系列机器人，乳名"大壮"。 现在"大壮"已实现独立行走、负重行走、上下楼梯、爬 ...

Investment Overview - The company intends to acquire up to 20.1667% equity in Ningbo Jujia New Materials Technology Co., Ltd. for a total price not exceeding 121 million RMB [1][5] - The acquisition will be made through cash payment and does not constitute a related party transaction or a major asset restructuring as per regulations [1][2] Target Company Information - Ningbo Jujia New Materials Technology Co., Ltd. was established on November 27, 2017, with a registered capital of approximately 14.2 million RMB [2][3] - The company specializes in technology services, research and development of bio-based materials, and manufacturing of synthetic materials [2][3] Financial Data - The target company's total assets as of the latest reporting period amount to approximately 389.4 million RMB, with total liabilities of about 280.8 million RMB [3] - The company reported a net loss of approximately 6.1 million RMB in the latest financial period [3] Transaction Details - The investment agreement is currently a non-binding intention, and further due diligence will be conducted before a formal agreement is signed [4][11] - The transaction is subject to various conditions, including the completion of due diligence and internal approvals from both parties [6][8] Strategic Importance - The acquisition is expected to enhance the company's capabilities in the new materials sector, particularly in high-performance LCP fibers and resins, which have applications in aerospace, industrial transport, and high-end cables [10] - Successful completion of the investment will support the company's expansion into emerging fields such as automotive electronics and humanoid robotics [10]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 本公告乃由本公司自願作出。 董事會欣然宣佈，於二零二五年六月三十日（聯交所交易時段後），本公司（作 為買方）已與賣方及Conflux訂立諒解備忘錄，內容有關收購目標公司全部股 權的潛在收購事項，前提為目標公司按照與本公司的協議完成收購Conflux 資產。 潛在收購事項須待本公司與賣方訂立正式協議後方可作實。因此，潛在收 購事項未必會進行。本公司將根據上市規則適時刊發公告。股東及本公司 潛在投資者於買賣本公司股份時務請審慎行事。 – 1 – INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED 領航醫藥及生物科技有限公 司 （於開曼群島註冊成立並於百慕達存續之有限公 司） （股份代 號：399） 自願公告 有關潛在收購事項的 諒解備忘錄 緒言 董事會欣然宣佈，於二零二五年六月三十日（聯交所交易時段後），本公司（作 為買方）已與賣方及Conflux訂立諒解備忘錄，內容有關潛在 ...

Core Viewpoint - 泰德医药 (Zhejiang Taide Pharmaceutical Co., Ltd.) has successfully listed on the Hong Kong Stock Exchange, with an initial trading price of 30.3 HKD and a closing price of 30.8 HKD, reflecting a slight increase of 0.65% on the first day of trading [1]. Summary by Relevant Sections IPO Details - The final offer price for the shares was set at 30.6 HKD, raising a total of 514.08 million HKD. After deducting estimated listing expenses of 85.31 million HKD, the net proceeds amounted to 428.77 million HKD [3][4]. Share Distribution - A total of 16,800,000 H-shares were issued, with an equal split of 8,400,000 shares allocated for public offering in Hong Kong and international offering [1]. Key Investors - The cornerstone investors for the IPO include Shiyao and Welight Capital [4]. Business Focus - The company primarily provides Contract Research Organization (CRO) services, focusing on peptide NCE discovery synthesis, and Contract Development and Manufacturing Organization (CDMO) services, which include peptide CMC development and commercial production. The services are mainly centered on providing Active Pharmaceutical Ingredients (API) rather than finished drugs [4]. Use of Proceeds - The funds raised will be utilized for expanding service capabilities and production capacity in the U.S. and China, increasing production capacity in China, establishing sales and after-sales service networks in more regions, and general corporate purposes [4]. Financial Performance - Projected revenues for 2022, 2023, and 2024 are 351 million RMB, 337 million RMB, and 442 million RMB, respectively. The net profits for the same years are expected to be 53.98 million RMB, 48.91 million RMB, and 59.17 million RMB [5][6].

朗迪集团：拟以不超1.21亿元收购聚嘉科技不超过20.1667%股权 智通财经6月30日电，朗迪集团(603726.SH)公告称，公司拟以现金方式收购宁波聚嘉新材料科技有限公 司不超过20.1667%的股权，总价不超过1.21亿元。宁波聚嘉新材料科技有限公司是目前行业内唯一具备 从高性能LCP纤维级基体树脂、改性树脂到高性能LCP纤维全产业链规模化生产及研发能力的高科技企 业。LCP作为一种高端特种工程材料，在航空航天、工业输送、光缆电缆、高端绳缆等关键领域应用广 泛，市场前景广阔。本次投资若顺利完成，将积极推动公司实现新材料板块补链强链，助力公司产品向 汽车电子、低空飞行、人形机器人等新兴领域拓展。 ...

Group 1 - The automotive industry is undergoing significant transformation, with product life cycles shortening from the traditional 10 years to 3-5 years, leading to a reduction in vehicle development cycles from 38 months to 22-24 months [2] - Increased market competition necessitates rapid responses to market feedback, making an open, flexible, agile, efficient, and reliable automotive R&D design system crucial for sustainable high-quality development in the industry [2] - The company is integrating AI technology throughout the automotive R&D process, launching an "automotive R&D digital intelligence system" to enhance development efficiency [2] Group 2 - The company is actively building an open collaborative ecosystem through strategic partnerships with leading semiconductor and AI firms, including NVIDIA, and academic institutions like Tsinghua University [3] - As of June 2024, the company became NVIDIA's sole solution consultant partner in the global automotive design sector, collaborating on software, hardware, and simulation platforms to drive innovation in automotive design technology [3] - The company's AI-powered automotive styling product "TAI" was officially launched in March 2025, featuring multiple functionalities such as text-to-image, line drawing rendering, multi-angle generation, background re-drawing, and 2D to 3D conversion, and is currently being promoted commercially [3]

Core Insights - The report emphasizes a focus on the technology sector for investment opportunities, particularly in growth stocks, as the market index has shown upward momentum [2][6]. - The report outlines a selection of ten key stocks, highlighting their respective industries, market capitalizations, earnings per share (EPS) forecasts, and price-to-earnings (PE) ratios for 2026 and 2027 [2][68]. Group 1: Key Stock Recommendations - **Neway Valve (603699.SH)**: A leading global industrial valve manufacturer, benefiting from a surge in LNG and marine engineering sectors, with expected overseas order growth of over 50% year-on-year in the first half of 2025 [11][12]. - **Yongxing Environmental (601033.SH)**: The sole operator of waste incineration in Guangzhou, with a projected capacity utilization rate of 79% and a commitment to high dividends, expecting a 174% increase in free cash flow in 2024 [17][18]. - **Aerospace Electronics (600879.SH)**: Focused on aerospace electronics and unmanned systems, with anticipated high growth driven by the commercial space industry and demand for satellite communication technologies [26][27]. - **Miaokelando (600882.SH)**: Positioned for long-term growth in the dairy sector, with a focus on product innovation and cost management, expecting significant revenue growth in the upcoming quarters [31][32]. - **Laopu Gold (6181.HK)**: A high-end gold jewelry brand with strong revenue growth, projected to achieve 8.51 billion yuan in revenue in 2024, benefiting from the expanding market for traditional gold products [36][38]. - **Jingzhida (688627.SH)**: Engaged in the semiconductor testing equipment sector, with significant market potential and expected strong performance due to key customer orders [42][43]. - **Shensanda A (000032.SZ)**: Positioned to benefit from the increasing demand for AI infrastructure and applications, with a strong foothold in public data services [47][48]. - **Sanqi Interactive (002555.SZ)**: Anticipating strong performance from new game releases, particularly the upcoming "Douluo Dalu: Hunting Soul World," with high player interest [53][56]. - **CATL (300750.SZ)**: Expected to maintain strong profit growth, with projected net profits of 66.1 billion yuan in 2025, driven by increasing demand for electric vehicle batteries [59][60]. - **Borui Pharmaceutical (688166.SH)**: Forecasted to achieve net profits of 2.6 billion yuan in 2025, with significant potential in the Amylin pipeline, which has attracted substantial investment interest [63][64]. Group 2: Financial Data Overview - The report provides detailed financial forecasts for the ten key stocks, including projected revenues and net profits for 2025 to 2027, highlighting the growth potential across various sectors [68]. - For instance, Neway Valve is expected to generate 74.53 billion yuan in revenue in 2025, with a net profit of 14.49 billion yuan, reflecting strong operational performance [68]. - CATL's projected revenue for 2025 is 472.43 billion yuan, with a net profit forecast of 66.13 billion yuan, indicating robust growth in the electric vehicle battery market [68].